Allergan signs $1.4bn eye drug deal with Molecular Partners
Will develop DARPin proteins to target AMD and other eye conditions
Read MoreSection: Research
Novartis reaffirms commitment to UK respiratory research site
Will slim down and redevelop Horsham facility
Read More
Antibody-drug conjugates on the up in cancer
Mylotarg served as a lesson of the pitfalls of ADCs: two years after it was pulled from the market some of the ADCs now in development will emerge as blockbusters
Read More
Novartis eye drug Jetrea effective in phase III
Pharma company and its partner ThromboGenics report positive trial data
Read MoreElan spins out research business
Drug discovery operations will form a new stand-alone company
Read More